Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionDnB Asset Management AS
Latest Disclosed Ownership141,232 shares
Latest Disclosed Value $ 18,605,904
DnB Asset Management AS reports 1.27% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - DnB Asset Management AS filed a 13F-HR form disclosing ownership of 141,232 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $18,605,904 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 139,457 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 1.27% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F Neurocrine Biosciences COM 64125C109 141,232 1,775 1.27 18,606 -5.94 0.0663
2026-02-05 2025-12-31 13F Neurocrine Biosciences COM 64125C109 139,457 15,349 12.37 19,779 13.53 0.0690
2025-11-12 2025-09-30 13F Neurocrine Biosciences COM 64125C109 124,108 9,168 7.98 17,422 20.60 0.0651
2025-08-12 2025-06-30 13F Neurocrine Biosciences COM 64125C109 114,940 -13,172 -10.28 14,447 1.95 0.0599
2025-05-15 2025-03-31 13F Neurocrine Biosciences common 64125C109 128,112 9,885 8.36 14,169 -12.20 0.0653
2025-02-12 2024-12-31 13F Neurocrine Biosciences COM 64125C109 118,227 3,500 3.05 16,138 22.08 0.0698
2024-11-12 2024-09-30 13F Neurocrine Biosciences COM 64125C109 114,727 39,781 53.08 13,219 28.12 0.0597
2024-07-05 2024-06-30 13F Neurocrine Biosciences common 64125C109 74,946 10,998 17.20 10,318 16.99 0.0492
2024-04-12 2024-03-31 13F Neurocrine Biosciences common 64125C109 63,948 -1,895 -2.88 8,820 1.66 0.0460
2024-01-04 2023-12-31 13F Neurocrine Biosciences common 64125C109 65,843 -14,189 -17.73 8,675 -3.64 0.0450
2023-10-13 2023-09-30 13F Neurocrine Biosciences common 64125C109 80,032 -3,645 -4.36 9,004 14.11 0.0538
2023-07-10 2023-06-30 13F/A-1 Neurocrine Biosciences common 64125C109 83,677 -12,440 -12.94 7,891 -18.89 0.0454
2023-07-06 2023-06-30 13F Neurocrine Biosciences common 64125C109 83,677 -12,440 7,891 0.0464
2023-04-20 2023-03-31 13F Neurocrine Biosciences common 64125C109 96,117 9,456 10.91 9,729 -6.01 0.0617
2023-01-12 2022-12-31 13F Neurocrine Biosciences common 64125C109 86,661 -1,105 -1.26 10,351 11.04 0.0730
2022-10-11 2022-09-30 13F Neurocrine Biosciences common 64125C109 87,766 -38,559 -30.52 9,322 -24.31 0.0719
2022-07-08 2022-06-30 13F Neurocrine Biosciences common 64125C109 126,325 -8,829 -6.53 12,314 -2.81 0.0866
2022-04-08 2022-03-31 13F Neurocrine Biosciences common 64125C109 135,154 -5,469 -3.89 12,671 5.79 0.0753
2022-01-12 2021-12-31 13F Neurocrine common 64125C109 140,623 22,344 18.89 11,977 5.57 0.0703
2021-10-15 2021-09-30 13F Neurocrine common 64125C109 118,279 -19,944 -14.43 11,344 -15.66 0.0737
2021-07-06 2021-06-30 13F Neurocrine common 64125C109 138,223 19,454 16.38 13,452 16.46 0.0891
2021-04-15 2021-03-31 13F Neurocrine common 64125C109 118,769 83,562 237.34 11,550 242.32 0.0843
2021-01-19 2020-12-31 13F Neurocrine common 64125C109 35,207 22,831 184.48 3,375 183.53 0.0296
2020-10-14 2020-09-30 13F Neurocrine common 64125C109 12,376 0 0.00 1,190 -21.14 0.0126
2020-07-08 2020-06-30 13F Neurocrine common 64125C109 12,376 1,477 13.55 1,510 60.02 0.0177
2020-04-17 2020-03-31 13F Neurocrine common 64125C109 10,899 -930 -7.86 943 -25.81 0.0139
2020-01-13 2019-12-31 13F Neurocrine common 64125C109 11,829 11,829 1,271 0.0125
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.